Prerpints.org logo
Preprint
Review

Staunch the Age Related Decline into Depression, Dementia, Diabetes, Obesity, Cancer, Long Covid, and Other Diseases with a Prebiotic, Probiotic, Postbiotic Triple Play

This version is not peer-reviewed.

Submitted:

30 January 2024

Posted:

30 January 2024

Read the latest preprint version here

A peer-reviewed article of this preprint also exists.

Abstract
“All diseases originate in the gut.” Hippocrates (400 BC) A healthy gut microbiome via the gut-brain-axis (GBA) elevates heart rate variability (HRV), a general measure of health and well-being. A dysbiotic gut microbiome, low in biodiversity and butyrate producers, triggers altered tryptophan metabolism and release of proinflammatory cytokines, predominantly TNF-α, IL-6, and IL-1β, that also characterize chronic inflammation, oxidative stress, and a multitude of diseases, all exhibiting low HRV. Gut dysbiosis upregulates IFN-γ and with it IDO (indoleamine 2,3 dioxygenase). Tryptophan pivots from serotonin synthesis to that of kynurenine, increasing the kynurenine to tryptophan ratio (KTR). An elevated KTR is positively linked to neurodegenerative and autoimmune diseases and negatively linked to HRV. Elevated IDO activity is not only enzymatic but also an intracellular signal transducer potentiated by TGF-β. This cytokine is the primary determinant of the TME. The triple play of a prebiotic (d-mannose), probiotic (bifidobacteria and lactobacilli), and postbiotic (butyrate) might improve intestinal barrier integrity, suppress the inflammatory cytokine triad, balance IFN-γ and TGF-β, depress KTR, elevate HRV, and extend lifespan.
Keywords: 
tumor microenvironment (TME)
;  
indoleamine 2
;  
3 dioxygenase (IDO)
;  
kynurenine
;  
short chain fatty acid (SCFA)
Subject: 
Medicine and Pharmacology  -   Pathology and Pathobiology
Bioactive Compounds with Application Potentials in Nutraceuticals and Nutricosmetics: Focus on Mechanism of Action and Application Science

Introduction

Pursuit of a healthier and happier lifestyle is a universal goal.
Better diet and more exercise are at the top of New Year’s resolutions. But eating favorite foods is one of the great joys in life and exercise, not so much. Balance is the key to achieving these goals, whether it be between the neurotransmitters glutamate and GABA or the pleiotropic cytokines IFN-γ and TGF-β. However, several supplements readily available may assist in this pursuit of balance.
Although this article cites an abundance of recent research supporting its content, it is speculative and the inferences are in part theoretical. It attempts to connect pleiotropic cytokines, gut dysbiosis, and disease with oxidative stress under the HRV umbrella (see Figure 1). Prebiotic d-mannose (a dietary fiber substitute), a probiotic rich in bifidobacteria and lactobacilli, and postbiotic butyrate (best SCFA) are proposed as partial solutions. HRV is proposed as a monitor of efficacy. It is the fifth vital sign and is more comprehensive and predictive in its assessment than that of the four traditional vital signs.

1. Oxidative Stress and Gut Dysbiosis

Aging reflects the accumulated damage over a lifetime wrought by oxidative stress. This stress arises when energy needs increase and reactive oxygen species (ROS) generated within mitochondria remain unquenched due to insufficient onboard antioxidants. Psychological stress induces oxidative stress by increasing circulating cortisol and norepinephrine, which generate mitochondrial ROS [1]. Mental stress is also linked with gut dysbiosis [2], which upregulates oxidative stress [3]. Excess ROS compromise mitochondrial efficiency and gut microbial diversity. Gut microbes themselves impact ROS generation.
Gut dysbiosis occurs when the gut microbiome is unbalanced, i.e., gut microbiota are not diverse and SCFA producing bacteria are in short supply. SCFAs are the end products of fermentation of dietary fibers by anaerobic intestinal bacteria and exert multiple beneficial effects on energy metabolism [4]
They are the primary energy substrate for colonic epithelial cells. Propionate and butyrate comprise 25% and 15% respectively of these SCFAs [5]. Acetate, which comprises ~60%, promotes obesity by stimulating insulin secretion and hyperphagia [6,7]. Propionate and butyrate stimulate secretion of GLP-1, which suppresses appetite and insulin secretion [8,9].
On the other hand, oxidative stress enhances acetate dependent lipogenesis, i.e., promotes obesity [10]. Persistent low grade oxidative stress is tightly linked to excitatory glutamate neurotransmission [11]. Glutamate producing gut bacteria outperform their GABA producing counterparts and create an imbalance in excitatory and inhibitory neurotransmission in the ANS [12]. The aging process and low grade chronic inflammation (increased ROS) are linked with upregulation of kynurenine and a shift in tryptophan metabolism from serotonin synthesis (decreased serotonergic inhibitory neurotransmission) to the kynurenine pathway [13], increasing KTR.

2. Altered Tryptophan Metabolism (ATM) and KTR

Tryptophan, an essential amino acid, from diet or synthesized by intestinal bacteria can follow one of three major metabolic pathways: 1) intestinal bacterial indole synthesis, 2) the kynurenine pathway in immune and epithelial cells, or 3) the serotonin pathway (90% of total body serotonin) in enteroendocrine aka enterochromaffin cells and initiation of vagal afferent signals [14]
During ATM tryptophan pivots away from the serotonin pathway and synthesis of serotonin and melatonin to the kynurenine pathway (see Figure 2). Inhibitory parasympathetic signals are suppressed due to the increase in excitatory glutamate activity. This pivot down-regulates bacterial indole synthesis with loss of indole induced glucagon-like peptide 1 (GLP-1). Benefits of GLP-1 include appetite suppression, stimulation of insulin [15], and decrease in fasting blood sugar [16], curbing obesity and T2DM [17]. Many of the same bacteria that produce SCFAs, e.g., Bifidobacteria and Lactobacilli, also synthesize indoles from tryptophan [18]. Although the end product NAD+ (see Figure 2) assists dysfunctional mitochondria in ATP production, what drives the ATM pivot is not exactly clear. However, IFN-γ, upregulated in females, is a cofactor for many enzymes in the kynurenine pathway (see Figure 2) and may drive the pivot [19] (see Figure 2). Tryptophan depletion lowers HRV (and increases KTR) [20]. Increased tryptophan intake (eggs) increases HRV, which appears to be driven by the subsequent increase in serotonin [21].
KTR, an indicator of rate-limiting IDO/TDO activity, is positively correlated with cardiovascular disease mortality [22,23], depression, bipolar disorder, schizoprenia, [24]
Alzheimer’s disease, fronto-temporal dementia, [25]
Parkinson’s disease [26], and neurological disease in general [27].
Increased KTR has also been reported in cancer [28], autoimmune disease, including RA [29], and SLE [30]. Infectious diseases are also linked to an elevated KTR [31] with a ratio that reflects severity [32,33]. This includes SARS CoV2 [34]. SARS CoV2 induced loss of ACE2 receptor bearing intestinal epithelial cells decreases absorption of the essential amino acid tryptophan [35] with additional negative influence on KTR and prognosis.
But there is another non enzymatic pathway from tryptophan that involves TGF-β.

3. IFN-γ and TGF-β

IFN-γ and TGF-β are polarizing cytokines (reciprocal relationship) [38] and counterbalance each other [39]. IFN-γ is pro-inflammatory and TGF-β is anti-inflammatory. When an imbalance arises, autoimmune disease/IFN-γ and cancer/TGF-β, two immunological opposites [40], can develop. These counterbalancing cytokines are in turn immuno-modulated by the gut microbiome. This is demonstrated by the utility of fecal microbiota transplant in both cancer and autoimmune disease.
Elevated IFN-γ characterizes parasitic infestations. In such patients this cytokine was positively associated with a good prognosis in Covid-19 [41]. Low baseline IFN-γ response could predict hospitalization [42] and post discharge fibrosis in COVID-19 patients [41]. On the other hand its reciprocal, TGF-β, was positively associated with Covid-19 severity [43] and fibrosis [44]. Even outside the TME TGF-β promotes fibrosis, counterbalanced by IFN-γ. These cytokines are directly linked to the KTR and IDO. IDO, the enzyme, works to restrain excessive or inappropriate immune activation in the TME [45]
However, IDO is not only an enzyme induced by IFN-γ (increased KTR) but also an intracellular signal transducer induced by TGF-β (TME) [46,47,48]
Pleiotropism is the expression of different traits by the same gene. IFN-γ can pivot from pro-inflammatory and anti-proliferative to tumor promoter and TGF-β can pivot from tumor suppressor to tumor promoter. What triggers the pleiotropic switch from tumor suppressor to tumor promoter for either IFN-γ or TGF-β is not clear, but may be related to the TME milieu, where TGF-β appears to dominate [49]. In an imbalanced (elevated TGF-β/IFN-γ) TGF-β may trigger fibrosis and the TME via paracrine transmission.
IFN-γ is generally considered pro-inflammatory but anti-proliferative. But in the TME it can induce PD-1 expression linked to metastasis (see Figure 3) [50]. TGF-β is generally considered anti inflammatory and a tumor suppressor, but in the TME it becomes a tumor promoter, triggering cancer associated fibroblasts (CAF), vascular endothelial growth factor (VEGF), and epithelial/endothelial mesenchymal transformation (EMT), possibly mediated by methylation of its epigenome. The switch seems to occur in the TME. The relative concentrations of IFN-γ and TGF-β [51] or local hypoxia [52] may instigate this. Interestingly tumors treated with low-dose IFN-γ acquired metastatic properties while tumors infused with high dose IFN-γ regressed [51].
Perhaps TGF-β concentration in the TME can trigger a pleiotropic switch in low dose IFN-γ but at a higher dose IFN-γ can modulate its reciprocal in the TME. Cancer cells can also produce TGF-β. Pleiotropic IFN-γ is linked with metastatic behavior via upregulation of PD-1 [53]. Angiotensin II stimulates the TGF-β signaling pathway [54]. This may in part explain the predilection for and severity of Covid-19 in males with comorbidities and for recurrent cancer in those previously in remission (see Figure 3). On the other hand, females are robust producers of type I interferon [55]. Type 1 IFNs (IFN-α and IFN-β) are first responders to any invading pathogen and trigger release of interferon-stimulated genes for synthesis of IFN-γ.
Its reciprocal, TGF-β, is vital to the maintenance of tolerogenesis and avoidance of autoimmunity. If TGF-β/IFN-γ is low, self recognition and tolerance may be compromised (autoimmunity) [56]. If TGF-β/IFN-γ is high, tumor associated antigens may be tolerated (cancer) [57]. An increased TGF-β/IFN-γ is also a risk factor for tissue fibrosis [58,59,60]

4. HRV and Inflammatory Cytokines, Cancer, Disease, Obesity

The cytokine triad of TNF-α [61,62,63], IL-6 [61,64], and IL-1β [61] are negatively linked to HRV and positively linked to CRP [64]. Cancer diagnosis and prognosis are linked to TNF-α [65], IL-1β [66,67], and IL-6. Low HRV can alert one to asymptomatic infection and inflammation [68,69], anxiety [70], depression [71,72], cognition and neurodegenerative disorders [73,74], psychosis spectrum disorders [75], cancer [76,77], cardiovascular disease [78,79], stroke [80,81], T2DM [82,83], severe Covid-19 [84], Long Covid [85,86,87], SLE [63,89], and RA [90]. Central aka visceral adiposity (WHR, WC) is negatively related to HRV and a much more sensitive indicator than BMI [91,92,93]. Peripheral obesity is not only not associated with a low HRV but is protective with elevated HRV [94].

5. Butyrate, D-mannose, and Probiotics

A.
Butyrate
Butyrate enhances mitochondrial function during oxidative stress [95] and rescues tryptophan [96]. Serotonin cannot cross the BBB, but tryptophan can, and by rescuing tryptophan, butyrate can increase brain serotonin (inhibitory neurotransmitter). Butyrate also suppresses IDO activity [97] and immuno-modulates IFN-γ and TGF-β [98]. Many of the same intestinal bacteria that produce butyrate possess glutamate dehydrogenase and can produce GABA [99] and the most recent research suggests that GABA can not only activate GABA receptors locally but may also enter circulation and cross the blood brain barrier (BBB) [100,101] to activate predominantly inhibitory signals. Some GABAergic nuclei in circumventricular organs are parasympathetic centers and don’t have a BBB.
The quantity of butyrate producing bacteria has generally been considered the gold standard for evaluating the health of the gut microbiome and the gut-brain axis [102], but neurotransmission by GABA, produced by these same bifidobacteria and lactobacilli, seems unacknowledged [103,104]. Butyrate producing gut microbiota [105], gut biodiversity, and production of SCFAs [106] are associated with elevated HRV. Unfortunately Bacteroidetes species (and butyrate) decline with age [107]. Butyrate alleviates obesity and related comorbidities [108,109,110]. But not all SCFAs have beneficial effects on human health. Acetate not only promotes obesity [7,111] but can also be used by tumor cells as an energy substrate during oxidative stress [112]. Postbiotic butyrate bypasses the negative effects [6] of Bacteroides produced acetate [113].
  • B. D-mannose
Prebiotic D-mannose improves the gut microbiome by increasing its biodiversity and butyrate producers, preventing gut dysbiosis [114,115]. D-mannose prevents diet induced obesity [116], positively associated with CRP and negatively associated with HRV [117]. Central adiposity is adverse and linked to elevated CRP, while peripheral adiposity is favorable and not so linked [118,119]. D-mannose not only downregulates gut dysbiosis by enhancing intestinal barrier integrity [114,115] but also suppresses the adipokine and cytokine triad (TNF-α, IL-6, IL-1β) [120,121,122], linked to cancer [123,124], cardiovascular disease [125], stroke [126], obesity [127], diabetes [128], neurodegenerative disease [129], and autoimmune disease [130,131].
D-mannose suppresses these autoimmune diseases like T1DM, asthma, and SLE [132] by suppressing IFN-γ [39,115]. D-mannose can suppress ERK (extracellular signal regulated kinase) signaling pathways (see Figure 3) [133] integral to TGF-β induced organ fibrosis [134], transformation of fibroblasts into CAFs [135], epithelial/endothelial mesenchymal transformation (EMT) [136], and VEGF synthesis [137]. D-mannose inhibits programmed cell death protein-1 (PD-1) (see Figure 3) [138], upregulated in Covid-19 [139]. This pathway to tumorigenesis is separate but complementary to that induced by TGF-β [140] (see Figure 3). Probiotics also increase HRV and have proven efficacious in LC [142,142]. They engage the prebiotic d-mannose and enhance the butyrate surge.

6. Other Considerations

There are other determinants of a low HRV, e.g., micronutrient deficiencies, especially vitamin D, which not only increases HRV [143] but also enhances gut biodiversity and growth of SCFA producers [144,145]. Imbalances, especially Ca:Mg [146], of many other micronutrient deficiencies, including B-12, C, E, magnesium, iron, zinc are associated with low HRV but the evidence is not definitive [147,148,149]. Vitamin B6 goes unnoticed, yet its active form (pyridoxal phosphate) is a required cofactor for conversion of glutamate to GABA and of tryptophan to serotonin and serotonin to melatonin. HRV reflects the state of our personal health and can be utilized to follow the efficacy of any changes in our lifestyle. KTR is negatively linked to HRV, but not yet commercially available [36,79]. CRP is also negatively correlated with HRV [146] and positively correlated with oxidative stress [149], smoking, heavy metal exposure [150], aromatic hydrocarbon exposure [151]. HRV is negatively linked to the western diet and sedentary lifestyle [152].

Conclusion

The described strong correlations between
  • HRV and gut dysbiosis
  • HRV and inflammatory cytokines
  • HRV/KTR/CRP and disease
  • Gut dysbiosis and disease
make diet (and exercise) the primary controllable causative links to good health. This triple play of prebiotic d-mannose, a probiotic of diverse butyrate producing bacteria, and postbiotic butyrate can provide a strong assist. But it all boils down to limiting oxidative stress (see Figure 1) and embracing antioxidants to maintain mitochondrial health. The deteriorating nutritional value of our food and the regrettable redirection of our choices driven by the flavor enhancing glutamate additive have accelerated our declining health. The triple combination of d-mannose, probiotics rich in bifidobacteria and lactobacilli, and butyrate should increase HRV and curb the risks for the discussed diseases and myriad other maladies. Adding exercise to this regimen further energizes HRV [153]. Monitoring a rising HRV and possibly a falling waistline [93,118] can provide positive feedback and boost incentive during the effort. This approach affords the individual an inexpensive and convenient path to a more healthful existence without necessarily forcing dietary and other lifestyle changes. The physiology and biochemistry are relatively straightforward, but biologic individuality and many other factors make transference to the clinical arena less straightforward. Unfortunately suitable clinical trials are unlikely, given the global emphasis and general preference for pharmaceutical solutions over a supplemental approach for any ailment. However, the approach described in this article doesn’t need a randomized controlled trial for validation, as HRV provides instantaneous feedback on efficacy for the most important individual versus a random group of individuals. Although obtaining an accurate HRV via bluetooth enabled chest strap, armband, finger sensor, or wristwatch can be tedious, HRV is especially useful in following the benefits of dietary changes [143] and significant benefits to a more healthful lifestyle and lifespan [154] await.
“Death sits in the bowel.” Hippocrates (400 BC)

References

  1. Flaherty RL, Owen M, Fagan-Murphy A, Intabli H, Healy D, Patel A, et al. Glucocorticoids induce production of reactive oxygen species/reactive nitrogen species and DNA damage through an iNOS mediated pathway in breast cancer. Breast Cancer Res. 2017 Mar 24;19(1):35. [CrossRef]
  2. Yang HL, Li MM, Zhou MF, Xu HS, Huan F, Liu N, et al. Links Between Gut Dysbiosis and Neurotransmitter Disturbance in Chronic Restraint Stress-Induced Depressive Behaviours: the Role of Inflammation. Inflammation. 2021 Dec;44(6):2448-2462. [CrossRef]
  3. Shandilya S, Kumar S, Kumar Jha N, Kumar Kesari K, Ruokolainen J. Interplay of gut microbiota and oxidative stress: Perspective on neurodegeneration and neuroprotection. J Adv Res. 2021 Sep 17;38:223-244. [CrossRef]
  4. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013 Sep;54(9):2325-40. [CrossRef]
  5. Liu H, Wang J, He T, Becker S, Zhang G, Li D, Ma X. Butyrate: A Double-Edged Sword for Health? Adv Nutr. 2018 Jan 1;9(1):21-29. [CrossRef]
  6. Ridler, C. Acetate promotes obesity via a gut–brain–β-cell axis. Nat Rev Endocrinol 12, 436 (2016). [CrossRef]
  7. Lin HV, Frassetto A, Kowalik Jr EJ, Nawrocki AR, Lu MM, Kosinski JR, et al. (2012) Butyrate and Propionate Protect against Diet-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms. PLoS ONE 7(4): e35240. [CrossRef]
  8. Psichas, A. , Sleeth, M., Murphy, K. et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes 39, 424–429 (2015). [CrossRef]
  9. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013 Aug 30;288(35):25088-25097. [CrossRef]
  10. Bose S, Ramesh V, Locasale JW. Acetate Metabolism in Physiology, Cancer, and Beyond. Trends Cell Biol. 2019 Sep;29(9):695-703. [CrossRef]
  11. Grignon, S. , & Deslauriers, J. ( 2015). The Reciprocal Effects of Oxidative Stress and Glutamate Neurotransmission. Medicine, Biology. [CrossRef]
  12. Baj A, Moro E, Bistoletti M, Orlandi V, Crema F, Giaroni C. Glutamatergic Signaling Along The Microbiota-Gut-Brain Axis. Int J Mol Sci. 2019 Mar 25;20(6):1482. [CrossRef]
  13. Sas K, Szabó E, Vécsei L. Mitochondria, Oxidative Stress and the Kynurenine System, with a Focus on Ageing and Neuroprotection. Molecules. 2018; 23(1):191. [CrossRef]
  14. Benech N, Rolhion N, Sokol H. Tryptophan metabolites get the gut moving. Cell Host Microbe. 2021 Feb 10;29(2):145-147. [CrossRef]
  15. Roager, H.M. , Licht, T.R. Microbial tryptophan catabolites in health and disease. Nat Commun 9, 3294 (2018). [CrossRef]
  16. Zhou Y, Chen Y, He H, Peng M, Zeng M, Sun H. The role of the indoles in microbiota-gut-brain axis and potential therapeutic targets: A focus on human neurological and neuropsychiatric diseases. Neuropharmacology. 2023 Nov 15;239:109690. [CrossRef]
  17. Liu JJ, Ching J, Wee HN, Liu S, Gurung RL, Lee J, et al, Subramaniam T, Sum CF, Sharma K, Kestenbaum BR, Lim SC. Plasma Tryptophan-Kynurenine Pathway Metabolites and Risk for Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care. 2023 Dec 1;46(12):2223-2231. [CrossRef]
  18. Ye X, Li H, Anjum K, Zhong X, Miao S, Zheng G, Liu W, Li L. Dual Role of Indoles Derived From Intestinal Microbiota on Human Health. Front Immunol. 2022 Jun 17;13:903526. [CrossRef]
  19. Gietl M, Burkert F, Seiwald S, Böhm A, Hofer S, Gostner JM, et al. Interferon-gamma Mediated Metabolic Pathways in Hospitalized Patients During Acute and Reconvalescent COVID-19. Int J Tryptophan Res. 2023 Feb 13;16:11786469231154244. [CrossRef]
  20. Booij, L. , Swenne, C. J. ( 60, 507–514. [CrossRef]
  21. Zahar S, Schneider N, Makwana A, Chapman S, Corthesy J, Amico M, et al. Dietary tryptophan-rich protein hydrolysate can acutely impact physiological and psychological measures of mood and stress in healthy adults. Nutr Neurosci. 2023 Apr;26(4):303-312. [CrossRef]
  22. Gáspár R, Halmi D, Demján V, Berkecz R, Pipicz M, Csont T. Kynurenine Pathway Metabolites as Potential Clinical Biomarkers in Coronary Artery Disease. Front Immunol. 2022 Feb 8;12:768560. [CrossRef]
  23. Lund A, Nordrehaug JE, Slettom G, Solvang SH, Pedersen EK, Midttun Ø, et al. Plasma kynurenines and prognosis in patients with heart failure. PLoS One. 2020 Jan 10;15(1):e0227365. [CrossRef]
  24. Marx, W. , McGuinness, A.J., Rocks, T. et al. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Mol Psychiatry 26, 4158–4178 (2021). [CrossRef]
  25. Heylen A, Vermeiren Y, Kema IP, van Faassen M, van der Ley C, Van Dam D, et al. Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD. Pharmaceuticals. 2023; 16(4):615. [CrossRef]
  26. Chen P, Geng X. Research progress on the kynurenine pathway in the prevention and treatment of Parkinson’s disease. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2225800. [CrossRef]
  27. Lovelace MD, Varney B, Sundaram G, Lennon MJ, Lim CK, Jacobs K, et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Via Neuropharmacology. 2017 Jan;112(Pt B):373-388. [CrossRef]
  28. Ala, M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. Eur J Pharmacol. 2021 Apr 5;896:173921. [CrossRef]
  29. Mangoni AA, Zinellu A. A systematic review and meta-analysis of the kynurenine pathway of tryptophan metabolism in rheumatic diseases. Front Immunol. 2023 Oct 23;14:1257159. [CrossRef]
  30. Eryavuz Onmaz, D. , Tezcan, D., Yilmaz, S. et al. Altered kynurenine pathway metabolism and association with disease activity in patients with systemic lupus. Amino Acids 55, 1937–1947 (2023). [CrossRef]
  31. Eller, S.K. , Däubener, W. (2015). Role of Kynurenine Pathway in Infections. In: Mittal, S. (eds) Targeting the Broadly Pathogenic Kynurenine Pathway. Springer, Cham. [CrossRef]
  32. Darcy CJ, Davis JS, Woodberry T, McNeil YR, Stephens DP, Yeo TW, Anstey NM. An observational cohort study of the kynurenine to tryptophan ratio in sepsis: association with impaired immune and microvascular function. PLoS One. e: 2011;6(6), 2011. [CrossRef]
  33. Fadhilah F, Indrati AR, Dewi S, Santoso P. The Kynurenine/Tryptophan Ratio as a Promising Metabolomic Biomarker for Diagnosing the Spectrum of Tuberculosis Infection and Disease. Int J Gen Med. 2023 Nov 28;16:5587-5595. [CrossRef]
  34. Lionetto L, Ulivieri M, Capi M, De Bernardini D, Fazio F, Petrucca A, et al. Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study. Biochim Biophys Acta Mol Basis Dis. 2021 Mar 1;1867(3):166042. [CrossRef]
  35. Jin B, Singh R, Ha SE, Zogg H, Park PJ, Ro S. Pathophysiological mechanisms underlying gastrointestinal symptoms in patients with COVID-19. World J Gastroenterol. 2021 ;27(19):2341-2352. 21 May. [CrossRef]
  36. Croitoru-Lamoury J, Lamoury FMJ, Caristo M, Suzuki K, Walker D, Takikawa O, et al. (2011) Interferon-γ Regulates the Proliferation and Differentiation of Mesenchymal Stem Cells via Activation of Indoleamine 2,3 Dioxygenase (IDO). PLoS ONE 6(2): e14698. [CrossRef]
  37. Chouraki V, Preis SR, Yang Q, Beiser A, Li S, Larson MG, et al. Association of amine biomarkers with incident dementia and Alzheimer’s disease in the Framingham Study. Alzheimers Dement. 2017 Dec;13(12):1327-1336. [CrossRef]
  38. Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, Neurath M. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today. 1997 Feb;18(2):61-4. [CrossRef]
  39. Gauthier T, Chen W. IFN-γ and TGF-β, Crucial Players in Immune Responses: A Tribute to Howard Young. J Interferon Cytokine Res. 2022 Dec;42(12):643-654. https://www.ncbi.nlm.nih. 9917.
  40. Elkoshi, Z. Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites? Front Immunol. 2022 Jan 25;13:821598. https://doiorg/10.3389/fimmu.2022. 8215. [Google Scholar]
  41. Abdel-Hamed, E.F. , Ibrahim, M.N., Mostafa, N.E. et al. Role of interferon gamma in SARS-CoV-2-positive patients with parasitic infections. Gut Pathog 13, 29 (2021). [CrossRef]
  42. Cremoni M, Allouche J, Graça D, Zorzi K, Fernandez C, Teisseyre M, et al. Low baseline IFN-γ response could predict hospitalization in COVID-19 patients. Front Immunol. 2022 Sep 26;13:953502. [CrossRef]
  43. Ferreira-Gomes, M. , Kruglov, A., Durek, P. et al. SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself. Nat Commun 12, 1961 (2021). [CrossRef]
  44. Chen, W. A potential treatment of COVID-19 with TGF-β blockade. Int J Biol Sci. 2020 Apr 21;16(11):1954-1955. [CrossRef]
  45. Wang XF, Wang HS, Wang H, Zhang F, Wang KF, Guo Q, et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell Immunol. 2014 May-Jun;289(1-2):42-8. [CrossRef]
  46. Pallotta MT, Rossini S, Suvieri C, Coletti A, Orabona C, Macchiarulo A, et al. Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme. FEBS J. 6: 2022 Oct;289(20), 2022. [CrossRef]
  47. Chen, W. IDO: more than an enzyme. Nat Immunol 12, 809–811 (2011). [CrossRef]
  48. Ye Z, Yue L, Shi J, Shao M, Wu T. Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications. J Cancer. 2019 Jun 2;10(12):2771-2782. [CrossRef]
  49. Chung JY, Chan MK, Li JS, Chan AS, Tang PC, Leung KT, et al. TGF-β Signaling: From Tissue Fibrosis to Tumor Microenvironment. Int J Mol Sci. 2021 Jul 15;22(14):7575. [CrossRef]
  50. Sri-Ngern-Ngam K, Keawvilai P, Pisitkun T, Palaga T. Upregulation of programmed cell death 1 by interferon gamma and its biological functions in human monocytes. Biochem Biophys Rep. 1: 2022 Oct 17;32, 2022. [CrossRef]
  51. Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020 Sep 29;8:49. [CrossRef]
  52. Chen, Z. , Han, F., Du, Y. et al. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Sig Transduct Target Ther 8, 70 (2023). [CrossRef]
  53. Numata Y, Akutsu N, Ishigami K, Koide H, Wagatsuma K, Motoya M, Sasaki S, Nakase H. Synergistic effect of IFN-γ and IL-1β on PD-L1 expression in hepatocellular carcinoma. Biochem Biophys Rep. 2022 ;30:101270. 5 May. [CrossRef]
  54. Ehanire T, Ren L, Bond J, Medina M, Li G, Bashirov L, et al. Angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction. J Mol Med (Berl). 2015 Mar;93(3):289-302. [CrossRef]
  55. Pujantell M, Skenteris NT, Claussen JM, Grünhagel B, Thiele RJ, Altfeld M. Sex-dependent differences in type I IFN-induced natural killer cell activation. Front Immunol. 2023 Dec 15;14:1277967. [CrossRef]
  56. Castenmiller C, Keumatio-Doungtsop BC, van Ree R, de Jong EC, van Kooyk Y. Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance. Front Immunol. 2021 Feb 19;12:643240. [CrossRef]
  57. M: in Cancer. [CrossRef]
  58. Hu ZJ, Xu J, Yin JM, Li L, Hou W, Zhang LL, et al. Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosis in COVID-19 Patients. Front Immunol. 2020 Sep 29;11:585647. [CrossRef]
  59. Frangogiannis, N. Transforming growth factor-β in tissue fibrosis. J Exp Med. e: 2020 Feb 13;217(3), 2020. [Google Scholar] [CrossRef]
  60. Ong CH, Tham CL, Harith HH, Firdaus N, Israf DA. TGF-β-induced fibrosis: A review on the underlying mechanism and potential therapeutic strategies. Eur J Pharmacol. 2021 Nov 15;911:174510. [CrossRef]
  61. Genot, Ernst. Heart-Rate Variability—More than Heart Beats? Front. Public Health, Sec. 11 September 2017. [CrossRef]
  62. Herhaus B, Thesing G, Conrad R, Petrowski K. Alterations in heart rate variability and pro-inflammatory cytokine TNF-alpha in individuals with panic disorder. Psychiatry Res. 1: 2023 Apr;322, 2023. [CrossRef]
  63. Thanou, A. , Stavrakis, S., Dyer, J.W. et al. Impact of heart rate variability, a marker for cardiac health, on lupus disease activity. Arthritis Res Ther18, 197 (2016). [CrossRef]
  64. Jones DR, Smyth JM, Engeland CG, Sliwinski MJ, Russell MA, Sin NL, et al. Affect variability and inflammatory markers in midlife adults. Health Psychol. 2020 Aug;39(8):655-666. [CrossRef]
  65. Wang, X. , Lin, Y. Tumor necrosis factor and cancer, buddies or foes?. Acta Pharmacol Sin 29, 1275–1288 (2008). [CrossRef]
  66. Rébé C, Ghiringhelli F. Interleukin-1β and Cancer. Cancers. 2020; 12(7):1791. [CrossRef]
  67. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016 Sep;37(9):11553-11572. [CrossRef]
  68. Williams DP, Koenig J, Carnevali L, Sgoifo A, Jarczok MN, Sternberg EM, Thayer JF. Heart rate variability and inflammation: A meta-analysis of human studies. Brain Behav Immun. 2019 Aug;80:219-226. [CrossRef]
  69. Cooper TM, McKinley PS, Seeman TE, Choo TH, Lee S, Sloan RP. Heart rate variability predicts levels of inflammatory markers: Evidence for the vagal anti-inflammatory pathway. Brain Behav Immun. 9: 2015 Oct;49, 2015. [CrossRef]
  70. Steffen PR, Bartlett D, Channell RM, Jackman K, Cressman M, Bills J, Pescatello M. Integrating Breathing Techniques Into Psychotherapy to Improve HRV: Which Approach Is Best? Front Psychol. 6: 2021 Feb 15;12, 2021. [CrossRef]
  71. Hartmann R, Schmidt FM, Sander C, Hegerl U. Heart Rate Variability as Indicator of Clinical State in Depression. Front Psychiatry. 2019 Jan 17;9:735. [CrossRef]
  72. Koch C, Wilhelm M, Salzmann S, Rief W, Euteneuer F. A meta-analysis of heart rate variability in major depression. Psychological Medicine. 2019;49(12):1948-1957. [CrossRef]
  73. Arakaki X, Arechavala RJ, Choy EH, Bautista J, Bliss B, Molloy C, et al. The connection between heart rate variability (HRV), neurological health, and cognition: A literature review. Front Neurosci. 1: 2023 Mar 1;17, 2023. [CrossRef]
  74. Liu KY, Elliott T, Knowles M, Howard R. Heart rate variability in relation to cognition and behavior in neurodegenerative diseases: A systematic review and meta-analysis. Ageing Res Rev. 2022 Jan;73:101539. [CrossRef]
  75. Benjamin BR, Valstad M, Elvsåshagen T, Jönsson EG, Moberget T, Winterton A, et al. Heart rate variability is associated with disease severity in psychosis spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Dec 20;111:110108. [CrossRef]
  76. Kloter E, Barrueto K, Klein SD, Scholkmann F, Wolf U. Heart Rate Variability as a Prognostic Factor for Cancer Survival - A Systematic Review. Front Physiol. 2018 ;9:623. 29 May. [CrossRef]
  77. Guo, Y, Koshy, S, Hui, D, Palmer, JL, Shin, K, Bozkurt, Mehtap, et al. Prognostic Value of Heart Rate Variability in Patients With Cancer. p: Journal of Clinical Neurophysiology 32(6), 20 December. [CrossRef]
  78. Kubota Y, Chen LY, Whitsel EA, Folsom AR. Heart rate variability and lifetime risk of cardiovascular disease: the Atherosclerosis Risk in Communities Study. Ann Epidemiol. 2017 Oct;27(10):619-625.e2. [CrossRef]
  79. Musialik-Łydka A, Sredniawa B, Pasyk S. Heart rate variability in heart failure. Kardiol Pol. 2003 Jan;58(1):10-6. https://pubmed.ncbi.nlm.nih. 1450.
  80. Lees T, Shad-Kaneez F, Simpson AM, Nassif NT, Lin Y, Lal S. Heart Rate Variability as a Biomarker for Predicting Stroke, Post-stroke Complications and Functionality. Biomark Insights. 2018 Jul 18;13:1177271918786931. [CrossRef]
  81. Buitrago-Ricaurte N, Cintra F, Silva GS. Heart rate variability as an autonomic biomarker in ischemic stroke. Arq Neuropsiquiatr. 2020 Nov;78(11):724-732. [CrossRef]
  82. Benichou T, Pereira B, Mermillod M, Tauveron I, Pfabigan D, Maqdasy S, et al. Heart rate variability in type 2 diabetes mellitus: A systematic review and meta-analysis. PLoS One. 2018 Apr 2;13(4):e0195166. [CrossRef]
  83. Schroeder, EB, Chambless, LE, Liao, D, Prineas, RJ, Evans, GW, Rosamond, WD, et al. Diabetes, Glucose, Insulin, and Heart Rate Variability: The Atherosclerosis Risk in Communities (ARIC) study. 6: Diabetes Care ; 28 (3), 1 March. [CrossRef]
  84. Hirten RP, Danieletto M, Tomalin L,Choi KH, Zweig M, Golden E, et al. e: Use of Physiological Data From a Wearable Device to Identify SARS-CoV-2 Infection and Symptoms and Predict COVID-19 Diagnosis: Observational Study J Med Internet Res 2021;23(2), 2021. [CrossRef]
  85. da Silva, A.L.G. , Vieira, L.d.P., Dias, L.S. et al. Impact of long COVID on the heart rate variability at rest and during deep breathing maneuver. Sci Rep 13, 22695 (2023). [CrossRef]
  86. Suh H-W, Kwon C-Y, Lee B. Long-Term Impact of COVID-19 on Heart Rate Variability: A Systematic Review of Observational Studies. Healthcare. 2023; 11(8):1095. [CrossRef]
  87. Mooren, F.C. , Böckelmann, I., Waranski, M. et al. Autonomic dysregulation in long-term patients suffering from Post-COVID-19 Syndrome assessed by heart rate variability. Sci Rep 13, 15814 (2023). [CrossRef]
  88. Garis, G. , Haupts, M., Duning, T. et al. Heart rate variability and fatigue in MS: two parallel pathways representing disseminated inflammatory processes. 44. [CrossRef]
  89. Novikova DS, Popkova TV, Panafidina TA, Il’ina AE, Kliukvina NG, Markelova EI, et al. Clinical significance of heart rate variability in patients with systemic lupus erythematosus. Ter Arkh. 2008;80(9):68-72. https://pubmed.ncbi.nlm.nih. 1955.
  90. Ingegnoli F, Buoli M, Antonucci F, Coletto LA, Esposito CM, Caporali R. The Link Between Autonomic Nervous System and Rheumatoid Arthritis: From Bench to Bedside. Front Med (Lausanne). 2020 Dec 7;7:589079. [CrossRef]
  91. Windham BG, Fumagalli S, Ble A, et al. The Relationship between Heart Rate Variability and Adiposity Differs for Central and Overall Adiposity. Journal of Obesity. 1: 2012 ;2012, 2012. [CrossRef]
  92. Farah BQ, Prado WL, Tenório TR, Ritti-Dias RM. Heart rate variability and its relationship with central and general obesity in obese normotensive adolescents. Einstein (Sao Paulo). 2013 Jul-Sep;11(3):285-90. [CrossRef]
  93. Yadav RL, Yadav PK, Yadav LK, Agrawal K, Sah SK, Islam MN. Association between obesity and heart rate variability indices: an intuition toward cardiac autonomic alteration - a risk of CVD. Diabetes Metab Syndr Obes. 2017 Feb 17;10:57-64. [CrossRef]
  94. Rastović M, Srdić-Galić B, Barak O, Stokić E. Association between anthropometric measures of regional fat mass and heart rate variability in obese women. Nutr Diet. 2017 Feb;74(1):51-60. [CrossRef]
  95. Rose, S. , Bennuri, S.C., Davis, J.E. et al. Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism.Transl Psychiatry 8, 42 (2018). [CrossRef]
  96. Rode, J, Yang, L, König, J, Hutchinson, AN, Wall, R, Venizelos, N, et al. Butyrate Rescues Oxidative Stress-Induced Transport Deficits of Tryptophan: Potential Implication in Affective or Gut-Brain Axis Disorders. 2: Neuropsychobiology ; 80 (3), 27 May. [CrossRef]
  97. Gao K, Mu CL, Farzi A, Zhu WY. Tryptophan Metabolism: A Link Between the Gut Microbiota and Brain. Adv Nutr. 2020 ;11(3):709-723. 1 May. [CrossRef]
  98. Siddiqui MT, Cresci GAM. The Immunomodulatory Functions of Butyrate. J Inflamm Res. 2021 Nov 18;14:6025-6041. [CrossRef]
  99. Strandwitz, P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018 Aug 15;1693(Pt B):128-133. [CrossRef]
  100. Liwinski T, Lang UE, Brühl AB, Schneider E. Exploring the Therapeutic Potential of Gamma-Aminobutyric Acid in Stress and Depressive Disorders through the Gut-Brain Axis. Biomedicines. 2023 Nov 24;11(12):3128. [CrossRef]
  101. Eepho, OI. , Bashir, AA.M., Oniyide, A.A. et al. Modulation of GABA by sodium butyrate ameliorates hypothalamic inflammation in experimental model of PCOS. BMC Neurosci 24, 62 (2023). [CrossRef]
  102. Stilling RM, van de Wouw M, Clarke G, Stanton C, Dinan TG, Cryan JF. The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis? Neurochem Int. 2016 Oct;99:110-132. [CrossRef]
  103. Strandwitz, P. , Kim, K.H., Terekhova, D. et al. GABA-modulating bacteria of the human gut microbiota. Nat Microbiol 4, 396–403 (2019). [CrossRef]
  104. O’Riordan KJ, Collins MK, Moloney GM, Knox EG, Aburto MR, Fülling C, et al. Short chain fatty acids: Microbial metabolites for gut-brain axis signalling. Mol Cell Endocrinol. 2022 Apr 15;546:111572. [CrossRef]
  105. Tsubokawa M, Nishimura M, Mikami T, Ishida M, Hisada T, Tamada Y. Association of Gut Microbial Genera with Heart Rate Variability in the General Japanese Population: The Iwaki Cross-Sectional Research Study. Metabolites. 2022; 12(8):730. [CrossRef]
  106. Domuschiev, I. , The relationship between Heart Rate Variability (HRV) and gut microbiota Mar 2023 ResearchGate https://www.researchgate. 3693. [Google Scholar]
  107. Fusco W, Lorenzo MB, Cintoni M, Porcari S, Rinninella E, Kaitsas F, et al. Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota. Nutrients. 2023; 15(9):2211. [CrossRef]
  108. Coppola S, Avagliano C, Calignano A, Berni Canani R. The Protective Role of Butyrate against Obesity and Obesity-Related Diseases. Molecules. 2021; 26(3):682. [CrossRef]
  109. Peng K, Dong W, Luo T, Tang H, Zhu W, Huang Y, et al. Butyrate and obesity: Current research status and future prospect. Front Endocrinol (Lausanne). 2023 Feb 24;14:1098881. [CrossRef]
  110. van Deuren T, Blaak EE, Canfora EE. Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use. Obes Rev. e: 2022 Oct;23(10), 2022. [CrossRef]
  111. Ridler, C. Acetate promotes obesity via a gut–brain–β-cell axis. Nat Rev Endocrinol 12, 436 (2016). [CrossRef]
  112. Schug, Z. , Vande Voorde, J., Gottlieb, E. The metabolic fate of acetate in cancer. Nat Rev Cancer 16, 708–717 (2016). [CrossRef]
  113. Baothman, O.A. , Zamzami, M.A., Taher, I. et al. The role of Gut Microbiota in the development of obesity and Diabetes. Lipids Health Dis 15, 108 (2016). [CrossRef]
  114. Dong, L. , Xie, J., Wang, Y. et al. Mannose ameliorates experimental colitis by protecting intestinal barrier integrity. Nat Commun 13, 4804 (2022). [CrossRef]
  115. Zhang W, Cheng H, Gui Y, Zhan Q, Li S, Qiao W, et al. Mannose Treatment: A Promising Novel Strategy to Suppress Inflammation. Front Immunol. 2021 Sep 27;12:756920. [CrossRef]
  116. Sharma V, Smolin J, Nayak J, Ayala JE, Scott DA, Peterson SN, et al. Mannose Alters Gut Microbiome, Prevents Diet-Induced Obesity, and Improves Host Metabolism. Cell Rep. 2018 Sep 18;24(12):3087-3098. [CrossRef]
  117. Haensel A, Mills PJ, Nelesen RA, Ziegler MG, Dimsdale JE. The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. Psychoneuroendocrinology. 1: 2008 Nov;33(10), 2008. [CrossRef]
  118. Ferreira, I, Snijder, MB, Twisk, JWR, van Mechelen, W, Kemper, HCG, Seidell, JC, et al. Central Fat Mass Versus Peripheral Fat and Lean Mass: Opposite (Adverse Versus Favorable) Associations with Arterial Stiffness? 1 June 2632; 89. [CrossRef]
  119. Cabral M, Bangdiwala SI, Severo M, Guimarães JT, Nogueira L, Ramos E. Central and peripheral body fat distribution: Different associations with low-grade inflammation in young adults? Nutr Metab Cardiovasc Dis. 2019 Sep;29(9):931-938. [CrossRef]
  120. Xiao P, Hu Z, Lang J, Pan T, Mertens RT, Zhang H, et al. Mannose metabolism normalizes gut homeostasis by blocking the TNF-α-mediated proinflammatory circuit. Cell Mol Immunol. 2023 Feb;20(2):119-130. [CrossRef]
  121. Torretta S, Scagliola A, Ricci L, Mainini F, Di Marco S, Cuccovillo I, et al. D-mannose suppresses macrophage IL-1β production. Nat Commun. 2020 Dec 11;11(1):6343. [CrossRef]
  122. Guo L, Hou Y, Song L, Zhu S, Lin F, Bai Y. D-Mannose Enhanced Immunomodulation of Periodontal Ligament Stem Cells via Inhibiting IL-6 Secretion. Stem Cells Int. 2018 Sep 9;2018:7168231. [CrossRef]
  123. Liu Y, Gao Y, Lin T. Expression of interleukin-1 (IL-1), IL-6, and tumor necrosis factor-α (TNF-α) in non-small cell lung cancer and its relationship with the occurrence and prognosis of cancer pain. Ann Palliat Med. 2021 Dec;10(12):12759-12766. [CrossRef]
  124. Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer. 2002 ;86(9):1396-400. 6 May. [CrossRef]
  125. Weber, B.N. , Giles, J.T. & Liao, K.P. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. Nat Rev Rheumatol 19, 417–428 (2023). [CrossRef]
  126. Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab. 2012 Sep;32(9):1677-98. [CrossRef]
  127. Zorena K, Jachimowicz-Duda O, Ślęzak D, Robakowska M, Mrugacz M. Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications. International Journal of Molecular Sciences. 2020; 21(10):3570. [CrossRef]
  128. Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine. 2016 Oct;86:100-109. [CrossRef]
  129. Ishijima T, Nakajima K. Inflammatory cytokines TNFα, IL-1β, and IL-6 are induced in endotoxin- stimulated microglia through different signaling cascades. Sci Prog. 2021 Oct;104(4):368504211054985. [CrossRef]
  130. Möller, B. , Villiger, P.M. Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases. 2006; 27. [Google Scholar] [CrossRef]
  131. Mikos H, Mikos M, Rabska-Pietrzak B, Niedziela M. The clinical role of serum concentrations of selected cytokines: IL-1β, TNF-α and IL-6 in diagnosis of autoimmune thyroid disease (AITD) in children. Autoimmunity. 2014 Nov;47(7):466-72. [CrossRef]
  132. Dhanalakshmi, M. , Sruthi, D., Jinuraj, K.R. et al. Mannose: a potential saccharide candidate in disease management. Med Chem Res 32, 391–408 (2023). [CrossRef]
  133. Nan F, Sun Y, Liang H, Zhou J, Ma X, Zhang D. Mannose: A Sweet Option in the Treatment of Cancer and Inflammation. Front Pharmacol. 2022 ;13:877543. 13 May. [CrossRef]
  134. Zhang J, Jiang N, Ping J, Xu L. TGF-β1-induced autophagy activates hepatic stellate cells via the ERK and JNK signaling pathways. Int J Mol Med. 2021 Jan;47(1):256-266. [CrossRef]
  135. Fang Z, Meng Q, Xu J, Wang W, Zhang B, Liu J, et al. Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives. Cancer Commun (Lond). 2023 Jan;43(1):3-41. [CrossRef]
  136. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia. 2004 Sep-Oct;6(5):603-10. https://doiorg/10.1593/neo. 0424.
  137. Xu J, Liu X, Jiang Y, Chu L, Hao H, Liua Z, Verfaillie C, Zweier J, Gupta K, Liu Z. MAPK/ERK signalling mediates VEGF-induced bone marrow stem cell differentiation into endothelial cell. J Cell Mol Med. 2008 Dec;12(6A):2395-406. [CrossRef]
  138. Zhang R, Yang Y, Dong W, Lin M, He J, Zhang X, et al. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proc Natl Acad Sci U S A. 2022 Feb 22;119(8):e2114851119. [CrossRef]
  139. Rha, MS. , Shin, EC. Activation or exhaustion of CD8+ T cells in patients with COVID-19. Cell Mol Immunol 18, 2325–2333 (2021). [CrossRef]
  140. Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, et al. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. Mol Oncol. 2022 Jun;16(11):2117-2134. [CrossRef]
  141. Young HA, Benton D. Heart-rate variability: a biomarker to study the influence of nutrition on physiological and psychological health? Behav Pharmacol. 2018 Apr;29(2 and 3-Spec Issue):140-151. [CrossRef]
  142. Alenazy MF, Aljohar HI, Alruwaili AR, Daghestani MH, Alonazi MA, Labban RS, et al. Gut Microbiota Dynamics in Relation to Long-COVID-19 Syndrome: Role of Probiotics to Combat Psychiatric Complications. Metabolites. 2022; 12(10):912. [CrossRef]
  143. Tak YJ, Lee JG, Kim YJ, Lee SY, Cho BM. 25-hydroxyvitamin D and its relationship with autonomic dysfunction using time- and frequency-domain parameters of heart rate variability in Korean populations: a cross-sectional study. Nutrients. 2014 Oct 16;6(10):4373-88. [CrossRef]
  144. Singh, P. , Rawat, A., Alwakeel, M. et al. The potential role of vitamin D supplementation as a gut microbiota modifier in healthy individuals. Sci Rep 10, 21641 (2020). [CrossRef]
  145. Wimalawansa, SJ. Vitamin D Deficiency: Effects on Oxidative Stress, Epigenetics, Gene Regulation, and Aging. Biology (Basel). 2019 ;8(2):30. 11 May. [CrossRef]
  146. Kim, YH. , Jung, KI. & Song, CH. Effects of Serum Calcium and Magnesium on Heart Rate Variability in Adult Women. Biol Trace Elem Res 150, 116–122 (2012). [CrossRef]
  147. Lopresti, AL. Association between Micronutrients and Heart Rate Variability: A Review of Human Studies. Adv Nutr. 2020 ;11(3):559-575. 1 May. [CrossRef]
  148. Zheltova AA, Kharitonova MV, Iezhitsa IN, Spasov AA. Magnesium deficiency and oxidative stress: an update. Biomedicine (Taipei). 2016 Dec;6(4):20. [CrossRef]
  149. Liu M, Dudley SC Jr. Magnesium, Oxidative Stress, Inflammation, and Cardiovascular Disease. Antioxidants (Basel). 2020 Sep 23;9(10):907. [CrossRef]
  150. Fan, T. , Fang, S.C., Cavallari, J.M. et al. Heart rate variability and DNA methylation levels are altered after short-term metal fume exposure among occupational welders: a repeated-measures panel study. BMC Public Health 14, 1279 (2014). [CrossRef]
  151. Liu K, Jiang J, Lin Y, Liu W, Zhu X, Zhang Y, et al. Exposure to polycyclic aromatic hydrocarbons, DNA methylation and heart rate variability among non-current smokers. Environ Pollut. 2021 Nov 1;288:117777. [CrossRef]
  152. Reginato E, Azzolina D, Folino F, Valentini R, Bendinelli C, Gafare CE, et al. Dietary and Lifestyle Patterns are Associated with Heart Rate Variability. J Clin Med. 2020 Apr 14;9(4):1121. [CrossRef]
  153. Souza PBd, de Araujo Borba L, Castro de Jesus L, Valverde AP, Gil-Mohapel J, Rodrigues ALS. Major Depressive Disorder and Gut Microbiota: Role of Physical Exercise. International Journal of Molecular Sciences. 2023; 24(23):16870. [CrossRef]
  154. Hernández-Vicente A, Hernando D, Santos-Lozano A, Rodríguez-Romo G, Vicente-Rodríguez G, Pueyo E, et al. Heart Rate Variability and Exceptional Longevity. Front Physiol. 2020 Sep 17;11:566399. [CrossRef]
Preprints 97651 g001
Figure 1. Pathways to a healthy HRV and enhanced lifespan are demonstrated. The western lifestyle includes an increased calcium to magnesium ratio, vitamin D deficiency, decreased antioxidants, toxins, e.g., smoking. TNF-α, IL-6, IL-1β comprise the triad. The trigger for the pleiotropic switch is not yet clear. Biologic individuality is also a prime determinant of differential pathway traffic.
Figure 1. Pathways to a healthy HRV and enhanced lifespan are demonstrated. The western lifestyle includes an increased calcium to magnesium ratio, vitamin D deficiency, decreased antioxidants, toxins, e.g., smoking. TNF-α, IL-6, IL-1β comprise the triad. The trigger for the pleiotropic switch is not yet clear. Biologic individuality is also a prime determinant of differential pathway traffic.
Preprints 97651 g001
Preprints 97651 g002
Figure 2. Altered tryptophan metabolism is demonstrated. NMDA-R is an excitatory glutamate receptor. Note the upregulating presence of the proinflammatory cytokine IFN-γ [24,36,37].
Figure 2. Altered tryptophan metabolism is demonstrated. NMDA-R is an excitatory glutamate receptor. Note the upregulating presence of the proinflammatory cytokine IFN-γ [24,36,37].
Preprints 97651 g002
Preprints 97651 g003
Figure 3. Proposed flow chart leading to cancer, demonstrating behavior of the cytokines TGF-β and IFN-γ in the tumor microenvironment (TME) that pleiotropically pivot from anti-inflammatory/tumor suppressor to tumor promoter (TGF-β) and from pro-inflammatory/tumor suppressor to tumor promoter (IFN-γ). TME=tumor microenvironment, CAF=cancer associated fibroblast, VEGF=vascular endothelial growth factor, EMT=epithelial or endothelial mesenchymal transformation, PD=programmed cell death protein-1, ERK=extracellular signal regulated kinase, IDO=indoleamine 2,3-dioxygenase. Figure 3 complements Figure 2.
Figure 3. Proposed flow chart leading to cancer, demonstrating behavior of the cytokines TGF-β and IFN-γ in the tumor microenvironment (TME) that pleiotropically pivot from anti-inflammatory/tumor suppressor to tumor promoter (TGF-β) and from pro-inflammatory/tumor suppressor to tumor promoter (IFN-γ). TME=tumor microenvironment, CAF=cancer associated fibroblast, VEGF=vascular endothelial growth factor, EMT=epithelial or endothelial mesenchymal transformation, PD=programmed cell death protein-1, ERK=extracellular signal regulated kinase, IDO=indoleamine 2,3-dioxygenase. Figure 3 complements Figure 2.
Preprints 97651 g003
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Downloads

377

Views

231

Comments

0

Subscription

Notify me about updates to this article or when a peer-reviewed version is published.

Email

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2025 MDPI (Basel, Switzerland) unless otherwise stated